Yuichi Takiguchi

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 912 citations

Medicine, Oncology, Pharmacology +14

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

Makiko Ono, Hitoshi Tsuda, Chikako Shimizu et al. · Breast Cancer Research and Treatment · 2011 · 306 citations

Medicine, Immunology, Oncology +15

Obstructive Sleep Apnea Syndrome Is Associated With Some Components of Metabolic Syndrome

Masakazu Kono, Koichiro Tatsumi, Toshiji Saibara et al. · CHEST Journal · 2007 · 245 citations

Medicine, Internal Medicine, Physiology +10

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama et al. · Cancer · 2017 · 243 citations · Full text

Medicine, Oncology, Pharmacology +16